Disease Detail

Profile Responses 0
Clinical Trials 100

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Therapy	Indication/Tumor Type	Response Type	Profile Response Detail

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT00577278	Phase II	Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan	A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan	Completed	USA	0
NCT00602693	Phase I	Sirolimus Allopurinol + Cyclophosphamide + Fludarabine	T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer	Completed	USA	0
NCT00671112	Phase I	Bortezomib + Everolimus	Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma	Terminated	USA	0
NCT01732913	Phase III	Idelalisib Rituximab	Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas	Terminated	USA \| SWE \| ROU \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| AUS	6
NCT01732926	Phase III	Idelalisib Bendamustine + Rituximab	Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas	Terminated	USA \| SWE \| POL \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| AUS	3
NCT01796171	Phase Ib/II	Lilotomab Betalutin Rituximab	A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)	Completed	USA \| TUR \| SWE \| POL \| NOR \| NLD \| ITA \| ISR \| IRL \| HUN \| HRV \| GBR \| FRA \| FIN \| ESP \| DNK \| CZE \| CHE \| CAN \| BEL \| AUT \| AUS	2
NCT01955499	Phase I	Ibrutinib + Lenalidomide	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Active, not recruiting	USA \| CAN	0
NCT01994382	Phase I	Cerdulatinib	Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma	Completed	USA	0
NCT02000934	Phase I	Mivavotinib	A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies	Completed	USA \| ITA \| GBR \| ESP	0
NCT02049541	Phase I	Buparlisib + Rituximab	Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma	Completed	USA	0
NCT02092909	Phase Ib/II	Bazlitoran	Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401)	Terminated	USA	0
NCT02106091	Phase I	AFM11	Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL	Terminated	USA \| POL \| DEU \| CZE	0
NCT02180724	Phase I	Acalabrutinib	An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia	Active, not recruiting	USA \| NLD \| ITA \| GRC \| GBR \| FRA \| ESP	0
NCT02339922	Phase II	Ixazomib + Rituximab	Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma	Active, not recruiting	USA	0
NCT02367040	Phase III	Rituximab Copanlisib	Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)	Active, not recruiting	USA \| TUR \| SVK \| ROU \| POL \| NZL \| LTU \| ITA \| IRL \| HUN \| GRC \| FRA \| ESP \| DEU \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	17
NCT02369016	Phase III	Copanlisib	Phase III Copanlisib in Rituximab-refractory iNHL	Completed	TUR \| POL \| ITA \| GRC \| BRA \| BGR	4
NCT02384954	Phase Ib/II	Nogapendekin alfa inbakicept + Rituximab	ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab	Terminated	USA	0
NCT02457598	Phase I	Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib	Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies	Terminated	USA \| GBR \| FRA	0
NCT02576496	Phase I	Tinostamustine	Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies	Completed	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CHE	0
NCT02604511	Phase II	Ibrutinib	Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing	Completed	USA	0
NCT02626455	Phase III	Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab	Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4)	Terminated	USA \| TUR \| SVK \| ROU \| POL \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUS	13
NCT02722668	Phase II	Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep	Active, not recruiting	USA	0
NCT02950220	Phase I	Ibrutinib + Pembrolizumab	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Completed	USA	0
NCT03010358	Phase Ib/II	Entospletinib + Obinutuzumab	Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	Completed	USA	0
NCT03015896	Phase Ib/II	Lenalidomide + Nivolumab	Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Active, not recruiting	USA	0
NCT03037645	Phase Ib/II	Vecabrutinib	Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers	Terminated	USA	0
NCT03053440	Phase III	Ibrutinib Zanubrutinib	A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)	Completed	USA \| SWE \| POL \| NLD \| ITA \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| AUS	0
NCT03085173	Phase I	EGFRt/19-28z/4-1BBL CAR T cells	A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies	Active, not recruiting	USA	0
NCT03133221	Phase II	Idelalisib	1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation	Active, not recruiting	USA	0
NCT03147885	Phase Ib/II	Selinexor	Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	Recruiting	USA	0
NCT03162536	Phase I	ARQ 531	Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies	Active, not recruiting	USA	0
NCT03225716	Phase Ib/II	Ibrutinib + Ulocuplumab	A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia	Terminated	USA	0
NCT03277729	Phase Ib/II	CD20 CAR-T cells + Cyclophosphamide + Fludarabine	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Active, not recruiting	USA	0
NCT03364231	Phase II	Umbralisib	Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma	Completed	USA	0
NCT03479268	Phase I	Ibrutinib + MLN4924	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma	Active, not recruiting	USA	0
NCT03480360	Phase III	Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus	Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression	Active, not recruiting	USA	0
NCT03498612	Phase II	Pembrolizumab	Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases	Active, not recruiting	USA	0
NCT03506373	Phase II	Ibrutinib + Ixazomib	Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia	Active, not recruiting	USA	0
NCT03537482	Phase I	APG-2575	APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies	Recruiting	USA \| AUS	0
NCT03557619	Phase I	Ethinylestradiol + Levonorgestrel + Venetoclax	A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies	Recruiting	USA \| AUS	0
NCT03571828	Phase I	AMG562	Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma	Terminated	USA \| DEU \| CAN \| BEL	0
NCT03601819	Phase I	Pacritinib	Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders	Terminated	USA	0
NCT03620903	Phase II	Rituximab Bortezomib Ibrutinib	Efficacy of First Line B-RI for Treatment Naive Waldenstrom's Macroglobulinemia	Active, not recruiting	GRC \| DEU	0
NCT03630042	Phase II	Pembrolizumab + Rituximab	Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia (PembroWM)	Completed	GBR	0
NCT03679624	Phase II	Daratumumab + Ibrutinib	Daratumumab Plus Ibrutinib in Patients With Waldenstrom's Macroglobulinemia	Terminated	USA	0
NCT03711578	Phase II	Tenalisib	Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)	Completed	USA \| AUS	0
NCT03740529	Phase Ib/II	Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib	A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL	Active, not recruiting	USA \| SWE \| POL \| ITA \| GBR \| FRA \| CHE \| AUS	2
NCT03779113	Phase Ib/II	HMPL-523	An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma	Active, not recruiting	USA \| POL \| ITA \| FRA \| FIN \| ESP \| DNK	0
NCT03786926	Phase Ib/II	HMPL-689	Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas	Active, not recruiting	USA \| POL \| ITA \| FRA \| FIN \| ESP	0
NCT03833180	Phase I	VLS-101	A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies	Completed	USA	0
NCT03884998	Phase I	Copanlisib + Nivolumab	Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma	Active, not recruiting	USA	0
NCT03920631	Phase I	Nivolumab	Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ)	Withdrawn	USA	0
NCT04043845	Phase I	Ibrutinib + LY3214996	ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies	Withdrawn		0
NCT04052854	Expanded access	Zanubrutinib	A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Patients With B-cell Malignancies	No longer available	USA	0
NCT04061512	Phase II	Cyclophosphamide + Dexamethasone + Rituximab Ibrutinib + Rituximab	Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW)	Recruiting	GBR	0
NCT04072458	Phase I	BP1002	A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies	Recruiting	USA	0
NCT04115059	Phase I	Dasatinib	Dasatinib In Waldenstrom Macroglobulinemia	Terminated	USA	0
NCT04260217	Phase I	APG-2575	APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenstrom Macroglobulinemia (MAPLE-1)	Completed	USA \| AUS	1
NCT04263480	Phase III	Carfilzomib + Ibrutinib Ibrutinib	Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)	Recruiting	GRC \| DEU \| AUT	0
NCT04273139	Phase II	Ibrutinib + Venetoclax	Ibrutinib + Venetoclax in Untreated WM	Active, not recruiting	USA	0
NCT04274738	Phase I	Ibrutinib + X4P-001	A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4	Completed	USA \| GRC	0
NCT04277637	Phase I	BGB-11417 + Zanubrutinib BGB-11417	Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies	Recruiting	USA \| NZL \| ITA \| GBR \| ESP \| DEU \| AUS	0
NCT04401020	Phase I	SAR442257	First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL	Active, not recruiting	USA \| NOR \| ESP \| CZE	1
NCT04540796	Phase I	JNJ-75348780	A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	Active, not recruiting	USA \| ISR \| GBR \| FRA \| ESP \| AUS	2
NCT04545762	Phase I	Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine	Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	Recruiting	USA	0
NCT04578600	Phase I	Azacitidine + Lenalidomide + Obinutuzumab	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Active, not recruiting	USA	0
NCT04624906	Phase II	Acalabrutinib + Bendamustine + Rituximab	Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (BRAWM)	Active, not recruiting	CAN	0
NCT04635683	Phase I	Lenalidomide + Ublituximab + Umbralisib	Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Withdrawn		0
NCT04665115	Phase II	Ibrutinib	Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)	Withdrawn	USA	0
NCT04728893	Phase II	ARQ 531	Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)	Recruiting	USA \| TUR \| ROU \| POL \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| AUS \| ARG	3
NCT04771572	Phase I	LP-118	Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.	Recruiting	USA	0
NCT04775745	Phase I	LP-168	Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.	Recruiting	USA	0
NCT04799275	Phase II	Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma	Recruiting	USA	0
NCT04830137	Phase I	NX-2127	A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies	Recruiting	USA	0
NCT04840602	Phase II	Ibrutinib + Rituximab + Venetoclax Ibrutinib + Rituximab	Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma	Recruiting	USA	0
NCT04842877	Phase II	DS-3201b	Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma	Active, not recruiting	FRA \| BEL	0
NCT04861779	Phase I	HSK29116	A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies	Unknown status	AUS	1
NCT04883437	Phase II	Acalabrutinib + Obinutuzumab	Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas	Recruiting	USA	0
NCT05003141	Phase I	PSB202	PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies	Unknown status	USA \| AUS	1
NCT05006716	Phase I	BGB-16673	A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies	Recruiting	USA \| TUR \| SWE \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS	3
NCT05020678	Phase I	Cyclophosphamide + Fludarabine NKX019	NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers	Recruiting	USA \| AUS	0
NCT05065554	Phase II	Acalabrutinib + Rituximab	ACALA-R In Anti-MAG Neuropathy Mediated Neuropathy	Recruiting	USA	0
NCT05131022	Phase I	NX-5948	Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies	Recruiting	USA \| NLD \| GBR	0
NCT05172700	Expanded access	Pirtobrutinib	Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer	Available		0
NCT05256641	Phase Ib/II	Acalabrutinib	Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma	Recruiting	USA	0
NCT05275504	Phase I	TT-01488	Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies	Unknown status	USA	0
NCT05293912	Phase I	SG2501	SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.	Recruiting	USA	0
NCT05424822	Phase I	JNJ-80948543	A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	Recruiting	USA \| POL \| ISR \| FRA \| DNK \| AUS	2
NCT05537766	Phase II	Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine	Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)	Active, not recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CHE \| AUT	0
NCT05602363	Phase I	AS-1763	AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma	Recruiting	USA	0
NCT05702853	Phase Ib/II	CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine	Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL	Recruiting	USA	0
NCT05734495	Phase II	Pirtobrutinib + Venetoclax	Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia	Recruiting	USA	0
NCT05753501	Phase I	ABBV-101	Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies	Recruiting	USA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN	1
NCT05780034	Phase I	AC0676	A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies	Recruiting	USA	0
NCT05797233	Phase I	Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells	Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies	Active, not recruiting	USA	0
NCT05952037	Phase II	BGB-11417	Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenstrom's Macroglobulinemia	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| AUS	1
NCT06340737	Phase I	Anti-CD22 CAR T cells	AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas	Recruiting	USA	0
NCT06510491	Phase II	Epcoritamab-bysp	Epcoritamab in Previously Treated WM	Not yet recruiting	USA	0
NCT06547866	Phase II	BGB-11417 + Zanubrutinib	Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia (WAZABI)	Not yet recruiting	FRA	0
NCT06561347	Phase II	Bendamustine + Rituximab + Zanubrutinib	Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM (ZEBRA)	Not yet recruiting	USA	0

ID	DOID:60901
Name	lymphoplasmacytic lymphoma
Definition	A B-cell lymphoma characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein.
Source	DiseaseOntology.org
Alt Ids	DOID:0050747
Path	disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma lymphoplasmacytic lymphoma

Disease Detail

Contact

Filtering

Sorting